Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
Zenodo (CERN European Organization for Nuclear Research) January 1, 2023 DOI: 10.5281/zenodo.16912423 via OpenAlex
Summary
AI-generated from the abstractA presentation by Michael Cunningham describes the pharmacological mechanism of Ariadne, a non-hallucinogenic 5-HT2A agonist, and its analogs. The work focuses on how these compounds interact with the 5-HT2A receptor to produce biological activity without inducing hallucinogenic effects, distinguishing their mechanism of action from classic psychedelics. The research explores the chemistry and biological activity of these molecules, contributing to understanding of agonist-antagonist dynamics in drug development.
Study at a glance
| Characteristics | Conference presentation Peer reviewed |
|---|---|
| Keywords | Mechanism biology Mechanism of action Agonist-antagonist Biological activity Chemistry |
| Key finding | Ariadne and its analogs act as non-hallucinogenic 5-HT2A agonists, offering a distinct pharmacological mechanism from hallucinogenic psychedelics. |
Abstract
Michael Cunningham - Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs (psychedelic molecules, 4th-5th September 2023, Prague, Czech Republic)